Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | LSS | P48449 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5849861 | 0.88 | ALDH1A1 (0.46) | PTGS2TSHRCA12CA1CA2 | |
| SCHEMBL5847978 | 0.88 | PTGS2 (0.41) | PTGS2CA12CA1CA2CA9 | |
| SCHEMBL5850188 | 0.83 | MMP1 (0.41) | PTGS2CA12CA1CA2CA9 | |
| SCHEMBL5850219 | 0.81 | TP53 (0.43) | PTGS2CA12CA1CA2CA9 | |
| SCHEMBL5848614 | 0.81 | CA12 (0.40) | PTGS2CA12CA1CA2CA9 | |
| SCHEMBL5849713 | 0.79 | PKM (0.46) | PTGS2SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL11883523 | 0.78 | CA1 (0.68) | TSHRNPSR1CA12CA1CA2 | |
| SCHEMBL5848712 | 0.77 | MMP2 (0.40) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL11089094 | 0.72 | GSK3B (0.45) | PTGS2KDM4EKMT2A | |
| SCHEMBL13296438 | 0.69 | TSHR (0.63) | TSHRNPSR1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7112605-B2 | Sulfonyl-containing 3,4-diaryl-3-pyrrolin-2-ones, preparation method, and medical use thereof | Research Institute of Materia Medica Chinese Acadamy of Medical Sciences (CN) | 2006-09-26 | — | — | US | claimed |
| US-20040029951-A1 | Sulfonyl-containing 3,4-diaryl-3-pyrrolin-2-ones, preparation method, and medical use thereof | RESEARCH INSTITUTE OF MATERIAL MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES; | 2004-02-12 | — | — | US | claimed |
| US-7112605-B2 | Sulfonyl-containing 3,4-diaryl-3-pyrrolin-2-ones, preparation method, and medical use thereof | Research Institute of Materia Medica Chinese Acadamy of Medical Sciences (CN) | 2006-09-26 | — | — | US | disclosed |
| US-20040029951-A1 | Sulfonyl-containing 3,4-diaryl-3-pyrrolin-2-ones, preparation method, and medical use thereof | RESEARCH INSTITUTE OF MATERIAL MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES; | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029951-A1 | Sulfonyl-containing 3,4-diaryl-3-pyrrolin-2-ones, preparation method, and medical use thereof | PTGS1, PTGS2, PTGER1 | PTGS2 2/4885TSHR 3463/4885NPSR1 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.